SHR-1209 ;placebo + SHR-1209 ;placebo + SHR-1209 ;placebo
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-familial Hypercholesterolemia
Conditions
Non-familial Hypercholesterolemia, Mixed Hyperlipidemia
Trial Timeline
Jul 30, 2021 → May 23, 2023
NCT ID
NCT04885218About SHR-1209 ;placebo + SHR-1209 ;placebo + SHR-1209 ;placebo
SHR-1209 ;placebo + SHR-1209 ;placebo + SHR-1209 ;placebo is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Non-familial Hypercholesterolemia. The current trial status is completed. This product is registered under clinical trial identifier NCT04885218. Target conditions include Non-familial Hypercholesterolemia, Mixed Hyperlipidemia.
What happened to similar drugs?
0 of 1 similar drugs in Non-familial Hypercholesterolemia were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04885218 | Phase 3 | Completed |
Competing Products
1 competing product in Non-familial Hypercholesterolemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| IBI306 + placebo + placebo + IBI306 | Innovent Biologics | Phase 3 | 47 |